Increased human hybridoma formation by electrofusion of human B cells with heteromyeloma SPAM-8 cells.
A fusion protocol was designed for the optimal production of hybridomas following electrofusion of human B cells with cells of the heteromyeloma fusion partner SPAM-8. Peripheral blood lymphocytes showed an average fusion efficiency of 0.4 x 10(-4) whereas Epstein-Barr virus-transformed B cells showed fusion efficiencies ranging from 6.2 x 10(-4) to 9.0 x 10(-4). Similar results were obtained with bone marrow-derived lymphocytes. Trypsin treatment of the cells prior to electrofusion further increased the fusion efficiency to 12.3 x 10(-4). In comparison, conventional polyethylene glycol-induced fusion resulted in a fusion efficiency of 0.8 x 10(-4). Thus, electrofusion of human B cells with SPAM-8 heteromyeloma cells introduced a 15-fold increase in hybridoma formation as compared to the conventional fusion method.
Panova
I
I
Center for Microbiology and Tumor Biology, Karolinska Institutet, Stockholm, Sweden.
Gustafsson
B
B
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D002459:Cell Fusion; D002461:Cell Line, Transformed; D055590:Electromagnetic Phenomena; D006801:Humans; D006825:Hybridomas / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D009101:Multiple Myeloma / Q000378:metabolism* / Q000473:pathology; D014357:Trypsin / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D014357:Trypsin